UroGen Pharma (URGN) Tops Q3 EPS by 17c

UroGen Pharma (NASDAQ: URGN) reported Q3 EPS of ($0.68), $0.17 better than the analyst estimate of ($0.85). Revenue for the quarter came in at $20.9 million versus the consensus estimate of $20.03 million.

For earnings history and earnings-related data on UroGen Pharma (URGN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery